Advisors Llc Orbi Med Capit... Net Worth

The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $30 Million dollars as of 13 August 2024. Advisors Capit owns over 500,000 units of scPharmaceuticals Inc stock worth over $1,292,104 and over the last 4 years Advisors sold SCPH stock worth over $28,669,273.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Advisors Capit SCPH stock SEC Form 4 insiders trading

Advisors has made over 5 trades of the scPharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Advisors bought 500,000 units of SCPH stock worth $2,000,000 on 13 August 2024.

The largest trade Advisors's ever made was selling 1,546,347 units of scPharmaceuticals Inc stock on 27 December 2023 worth over $28,669,273. On average, Advisors trades about 743,807 units every 221 days since 2020. As of 13 August 2024 Advisors still owns at least 252,858 units of scPharmaceuticals Inc stock.

You can see the complete history of Advisors Capit stock trades at the bottom of the page.

Insiders trading at scPharmaceuticals Inc

Over the last 7 years, insiders at scPharmaceuticals Inc have traded over $5,999,254 worth of scPharmaceuticals Inc stock and bought 6,409,552 units worth $61,370,807 . The most active insiders traders include Capital Management, L.P.Ra ..., Jonathan Silverstein, and Advisors Llc Orbi Med Capit.... On average, scPharmaceuticals Inc executives and independent directors trade stock every 112 days with the average trade being worth of $1,808,281. The most recent stock trade was executed by Leonard D Schaeffer on 26 August 2024, trading 11,347 units of SCPH stock currently worth $29,275.

What does scPharmaceuticals Inc do?

scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.

Complete history of Advisors Capit stock trades at Alpine Immune Sciences Inc and scPharmaceuticals Inc

scPharmaceuticals Inc executives and stock owners

scPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Tucker,
  President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Director
• John H. Tucker,
  Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director
• Rachael Nokes,
  Senior Vice President - Finance, Principal Accounting Officer
• Rachael Nokes,
  Sr. VP of Fin. & Principal Accounting Officer
• Jack Khattar,
  Independent Chairman of the Board
• Frederick Hudson,
  Independent Director
• Mette Agger,
  Independent Director
• Klaus Veitinger,
  Independent Director
• Minnie Baylor-Henry,
  Independent Director
• Leonard Schaeffer,
  Independent Director
• Mason Freeman,
  Independent Director
• Katherine Taudvin,
  Director, Corporate Development, Investor Relations
• Sara Bonstein,
  Independent Director
• Michael D. Hassman,
  Sr. VP of Technical Operations
• Dr. John Mohr Pharm.D.,
  Sr. VP of Clinical Devel. & Medical Affairs
• Capital Management, Llcra C...,
  
• Invest A/S Lundbeckfond,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Dorothy Coleman,
  Director
• Jonathan Silverstein,
  Director
• Pharmaceutical Industries L...,
  
• Troy A. Ignelzi,
  Chief Financial Officer
• Abraham Ceesay,
  Chief Operating Officer
• Kush Parmar,
  Director
• Andrew J. Schwab,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Capital Management, L.P.Ra ...,
  
• Partners Iv, Llc5 Am Co Inv...,
  
• William Tober Abraham,